Whose Table Is It? How Some Patient Organizations Are Becoming The Drivers Of Drug Development

For decades, disease registries have been the quiet backbone of rare and complex disease research. Most were built and run by companies or academic groups to be observed, not to make decisions from, and many leave patient families carrying the cost of manual data entry and scattered records. Something is shifting. A small number of patient organizations have stopped waiting for an invitation to the research table and started setting it themselves, running their own registries and becoming genuine drivers of drug development rather than advisory voices.

Join Craig Lipset and Dr. Derk Arts for an honest conversation about what that shift really looks like, and what it does not. They trace how some patient groups are moving from advisory roles to deriskers, the ones willing to run the novel trial designs that sponsors hesitate to try. They map the path from registry and natural-history data to real-world evidence, drug repurposing, and master protocols that cluster related conditions under one design. And they are candid about the limits, why this is a blueprint still being built rather than a finished playbook, and what has to be true for a federation of small groups to run it at all.

If you lead clinical development, this is a look at an efficiency lever that has been hiding in plain sight, and a practical view of what patient organizations are starting to make possible.